Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
FOXO4 10mg
Free shipping on orders over €200
- If a product doesn't match the specification on its published COA, contact us with your batch number: we investigate against the lot's report and replace any product that fails it, at no cost to you.
- Contact us within 48 hours of delivery with photos of the outer box, inner packing, and any affected vials with labels legible. Confirmed transit damage is replaced at no cost to you.
3–7 days most of the EU · 10–14 Nordics/Baltics
Standard EU from €4.99 (RO) · core EU GLS €17.99 · Nordics/Baltics €12.99–€15.99 · Dispatched within 1–2 business days · Free shipping over €200.00 · no customs paperwork (EU) · via EU carrier network
€200.00 away from free shipping over €200.00. Under that, standard EU shipping is €17.99 (GLS, most of the EU).
How Paysera and SEPA work
- Pay: send a manual SEPA transfer using the IBAN we email you, or, where checkout offers it for your address, approve a SEPA transfer in your own bank via Paysera's hosted page.
- We confirm — Paysera notifies us instantly, or we match a manual transfer when it arrives (usually 1 business day).
- We dispatch — confirmed orders typically ship within 1–2 business days.
Card payments are not currently offered. There is no card processor on this checkout.
Research-grade FOXO4. Class-level specification ≥98%. Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Due to legal and regulatory requirements, this product cannot be shipped to: Croatia, Italy, Lithuania, and Slovenia.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
When This Product May Not Suit Your Research
- ⚠If your research requires GMP-grade material for clinical applications — research-grade peptides are not intended for clinical use.
- ⚠If your lab lacks proper cold storage (-20°C freezer) — this peptide's stability may be compromised at higher temperatures.
- ⚠If your study protocol requires FDA-approved reference standards — contact USP or a certified reference material provider.
Published laboratory reports are available for selected lots. Check each report for its result and stated method. For research purposes only.
Janoshik report published when available
Dispatched within 1–2 business days, shipping from €4.99 in Romania, from €12.99 across the rest of Europe
Class-level specification on record; independent Janoshik report on selected lots
About FOXO4 10mg
About FOXO4 10mg
What is FOXO4-DRI?
Senescent cells — the ones that have stopped dividing but refuse to die — stay alive by sequestering p53 in the nucleus through a FOXO4-p53 interaction. FOXO4-DRI disrupts that interaction. When the partnership breaks, p53 is free to do what it normally does in damaged cells: trigger apoptosis. The senescent cell dies. The healthy cell next door, which does not depend on FOXO4-p53 for survival, is unaffected.
Peter de Keizer at Erasmus University published this mechanism in 2017. It was the first peptide-based senolytic — a compound that selectively kills senescent cells.
Mechanism of Action
The D-retro-inverso trick
DRI stands for D-retro-inverso. All the amino acids are D-form (mirror image of natural L-amino acids) and the sequence runs backwards. This makes the peptide invisible to proteases — enzymes that normally chop up peptides cannot recognize D-amino acid substrates. So FOXO4-DRI has the binding specificity of the natural FOXO4 sequence but the metabolic stability that natural peptides lack.
Mechanism
Competes with endogenous FOXO4 for p53 binding. In senescent cells, FOXO4 keeps p53 trapped in the nucleus and away from the mitochondria where it would trigger apoptosis. FOXO4-DRI outcompetes this interaction, releasing p53. Free p53 translocates to mitochondria and initiates the intrinsic apoptosis pathway. Only cells that depend on FOXO4-p53 for survival are affected — which is specifically senescent cells.
Research Overview
Storage
Lyophilized at -20°C. Reconstituted: 2-8°C, use within 4 weeks.
Quality
Class-level specification ≥98%. Sold and shipped from the EU by CERTALAB S.R.L.
Product Specifications
- Molecular weight: ~5,500 Da
- Purity: ≥98% (class-level specification)
- Form: Lyophilized powder
- SKU: CP-F410
Independent reports, where on record, are searchable by batch or report code. View reports →
For research purposes only. Not for human consumption.
Specification Summary
About FOXO4 10mg
About FOXO4 10mg
What is FOXO4-DRI?
Senescent cells — the ones that have stopped dividing but refuse to die — stay alive by sequestering p53 in the nucleus through a FOXO4-p53 interaction. FOXO4-DRI disrupts that interaction. When the partnership breaks, p53 is free to do what it normally does in damaged cells: trigger apoptosis. The senescent cell dies. The healthy cell next door, which does not depend on FOXO4-p53 for survival, is unaffected.
Peter de Keizer at Erasmus University published this mechanism in 2017. It was the first peptide-based senolytic — a compound that selectively kills senescent cells.
Mechanism of Action
The D-retro-inverso trick
DRI stands for D-retro-inverso. All the amino acids are D-form (mirror image of natural L-amino acids) and the sequence runs backwards. This makes the peptide invisible to proteases — enzymes that normally chop up peptides cannot recognize D-amino acid substrates. So FOXO4-DRI has the binding specificity of the natural FOXO4 sequence but the metabolic stability that natural peptides lack.
Mechanism
Competes with endogenous FOXO4 for p53 binding. In senescent cells, FOXO4 keeps p53 trapped in the nucleus and away from the mitochondria where it would trigger apoptosis. FOXO4-DRI outcompetes this interaction, releasing p53. Free p53 translocates to mitochondria and initiates the intrinsic apoptosis pathway. Only cells that depend on FOXO4-p53 for survival are affected — which is specifically senescent cells.
Research Overview
Storage
Lyophilized at -20°C. Reconstituted: 2-8°C, use within 4 weeks.
Quality
Class-level specification ≥98%. Sold and shipped from the EU by CERTALAB S.R.L.
Product Specifications
- Molecular weight: ~5,500 Da
- Purity: ≥98% (class-level specification)
- Form: Lyophilized powder
- SKU: CP-F410
Independent reports, where on record, are searchable by batch or report code. View reports →
For research purposes only. Not for human consumption.
What research shows
Selected peer-reviewed studies from the published literature. Each describes laboratory or preclinical findings and is attributed to the cited study, not to this product. For research use only — not medical guidance.
Senolytic proof-of-concept
In cell-culture and mouse research, a FOXO4-based interfering peptide (FOXO4-DRI) induced targeted apoptosis of senescent cells and was reported to restore tissue homeostasis in response to chemotoxicity and aging.
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell (2017). PMID: 28340339FOXO4-p53 peptide design
In in-vitro and molecular-modelling research, the FOXO4-TP53 interaction was modelled to design senolytic peptides such as FOXO4-DRI for the elimination of senescent cancer cells.
Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. EBioMedicine (2021). PMID: 34689087Citations are provided for research reference. CertaPeptides (CERTALAB S.R.L.) is a reseller, not a manufacturer, and makes no medical, therapeutic, or efficacy claims. Products are for laboratory research use only and are not for human or animal consumption.
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every vial label carries a code. Look it up on our Verify page: it shows what CertaPeptides publishes for that code and, for a withdrawn lot, that the lot was withdrawn and why. If yours is withdrawn, or if the code on your label finds nothing, email us that code.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, GLS for most EU destinations, TCE Worldwide for the remaining cross-border EU and non-EU markets (UK, Switzerland). Delivery 1–15 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with escalation to ANPC and alternative dispute resolution (SAL) available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
